Surfix is redefining POC testing by co-developing customized immuno-based assays in collaboration with partners. With detection sensitivities in the subpicogram/mL range, these advanced assays leverage Surfix’s photonic diagnostics platform to deliver beyond lab-level sensitivity across various sample types. The platform’s flexibility supports an extensive range of POC applications.

Recent Projects

Our recent collaborations demonstrate the broad capabilities of our platform and are captured in our whitepapers:

• > COVID-19 Antigen Detection: Rapid and reliable identification of viral antigens.
• > Multiplex Diagnostics for Sepsis: Detection of IL-6, PCT, and CRP biomarkers across a wide dynamic range.
• > Cancer Diagnostics: Partnered projects targeting several cancer types, with additional applications currently in development.

Expanding the Pipeline

The versatility of Surfix’s photonic diagnostics platform enables applications like:

• > Cardiovascular diseases
• > Infectious diseases
• > Neurodegenerative conditions
• > Oncology
• > Inflammation

These advancements underline the platform’s transformative potential for diverse diagnostic challenges. For an in-depth look at our achievements, explore our comprehensive whitepapers. 

Founded in 2011 as a spin-off from Wageningen University & Research (WUR), Surfix initially focused on R&D services for nanocoatings, supporting applications such as biosensors and microfluidic devices. Over the next decade, Surfix’s expertise in nanotechnology laid the foundation for a significant pivot in 2021: start of the development of its groundbreaking photonic diagnostics platform.

Today, Surfix specializes in co-developing tailored POC assays, delivering rapid and precise immuno-based biomarker detection for the POC market.

Building for the Future

The continued evolution of Surfix’s platform is strengthened by the PhotonMed project (Chips JU), a collaborative initiative aimed at accelerating the integration of photonics-based medical devices into healthcare systems. This project highlights Surfix’s commitment to advancing diagnostics and transforming global health.